In summary, our results indicate that RE exerts antitumor activity on both colon and pancreatic cancers, probably through the up-regulation of GCNT3 and the down-regulation of miR-15b, and constitutes a promising therapeutic tool in the treatment of patients suffering from these diseases. This evidence concerns the gene GCNT3 and pancreatic neoplasm.